Clinical Analysis Of144Cases Of Primary Gastrointestinal Lymphoma

Purpose: To explore the clinical features of primary gastrointestinallymphoma and improve the level clinician in early diagnosis and effectivetreatment on this disease.Methods: A retrospective analysis in January2007to December2010jilinuniversity affiliated hospital confirmed by histopathologic144PGIL patientsclinical and follow-up data. Collecting the patient’s clinical manifestation,laboratory examination, endoscopic examination, imaging examination,pathological type, immunohistochemical, etc, treatment and follow-up data.Using SPSS21.0software, Kaplan Meier-method applied survival analysis,counting data in accordance with the chi-square test, P <0.05, with statisticalsignificance.Results:(1)Prognosis of single factor analysis showed:<60years old agegroup3year survival rate was significantly higher than that of≥60age group,（77.0%，57/74vs44.3%，31/70）（P=0.007）. Gastric lymphoma3year survivalrate is better than that of intestinal lymphoma group.（77.4%，65/84vs51.7%，31/60）（P=0.001）. Lesions≥10cm group3year survival rate was30.8%(4/13)is lower than the lesion <10cm3year survival rate was70.2%(92/131)(P=0.004). High expression of KI-67group (>25%)3year survival rate is lowerthan the low expression group (25%),（44.7%，17/38vs74.5%，79/106）（P=0.001）. Patients with early (Ⅰ, Ⅱ)3year survival rate was74.5%(70/94) higher than the middle-late patients with stage (Ⅲ, Ⅳ)3year survival rate was52.0%(26/50)(P=0.006). PS score0-1points3year survival rate is higherthan2to4groups, were74.8%(77/103),46.3%(19/41)(P=0.001). Surgeryplus chemotherapy group3year survival rate was78.4%(29/37), its survivaladvantage is better than pure surgery group (57.8%) and pure chemotherapygroup (56.1%)(P=0.048,0.037), immune treatment+chemotherapy group3year survival rate was85.7%(18/21), significantly better than the purechemotherapy group (P=0.020). Gender, duration, B symptoms, anemia, LDHhad no significant effect on PGIL survival (P>0.05).(2) The intestinallymphoma in patients with obstruction rate was20%(12/60) higher than that ofgastric lymphoma obstruction rate was4.8%(4/84)(P=0.004). Intestinallymphoma group perforation rate is significantly higher than that of gastriclymphoma,11.7%(7/60) vs2.4%(2/84)(P=0.023).(3) The proportion ofintestinal lymphoma group issued within three months (48.3%,29/60)significantly higher than the gastric lymphoma group (29.8%,25/84)(P=0.023).(4) The stomach and intestine MALT group3year survival rates werebetter than treated parts of MALT group treated with3year survival rate(stomach91.7%vs66.7%, P=0.007)(im72.7%vs39.5%, P=0.013).(5)84cases of gastric lymphoma in patients with77HP routine inspections, gastricMALT lymphoma treated group HP infection rate was94.1%(32/34) higherthan the stomach of MALT lymphoma treated group and60.5%(26/43)(P=0.001).(6) Endoscopy and CT examination to diagnosis rate is low, only27.3% (35/128) and12.5%(10/74).Conclusion:(1) The prognosis of the single factor analysis results showedthat age, primary site, tumor size, KI-67expression level, clinical stage, PSscore, treatment has a significant influence on survival rate (P <0.05).(2)Therate of intestinal lymphoma obstruction and perforation rate is relatively highgastric lymphoma.(3)The intestinal lymphoma visits a relatively short time.(4)The prognosis of gastric and intestinal MALT lymphoma treated better than ofMALT lymphoma treated with parts.(5)In patients with gastric MALTlymphoma treated with a stomach of MALT lymphoma treated patients with HPinfection rate is high.(6) Endoscopy and CT examination for PGIL diagnosisrate is low.